Limited Funding Opportunity: Administrative Supplements to P30 CCSG and P50 SPORE Grants for Clinical Testing of Cell-based Immunotherapies in Pediatric Solid Tumors (Can-ACT)

The goal of this solicitation is to give investigators at NCI-Designated Cancer Centers and SPOREs an opportunity to submit one year supplement proposals to advance cell therapy strategies into clinical testing. The application must propose a clinical trial for a novel cell therapy treatment (or a combination with a cell therapy) of a solid tumor generally occurring in pediatric patients.

Download the RFA

IMPORTANT DETAILS

• Supplement requests may not exceed $1million in total costs and the project period is for one year

• The successful applicant will be ready to go with an IRB-approved clinical trial within the first three months of the award, which will begin on or around Sept 1, 2025.

DF/HCC LOI & INTERNAL DEADLINE

 Please reach out as soon as possible if you are interested in being considered with a supplement application for the DF/HCC P30 Cancer Center Support Grant (CCSG). 

Letter of Intent (LOI) to DF/HCC : July 1, 2025 (noon) to deborah_goff@dfci.harvard.edu​​​​​​
Full Application Deadline to NCI: August 1, 2025 (internal deadline July 25, 2025)

The LOI should contain the following:

• Name, academic title, institutional affiliation of applicant(s).

• One-page summary of research plan, including status of IND for the clinical trial proposed. 

• NIH biosketch of applicant(s)